Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Urine Test Could Replace Painful Kidney Biopsies for Lupus Patients

By LabMedica International staff writers
Posted on 01 Nov 2025

Lupus is an autoimmune disorder that causes the immune system to attack the body’s own tissues and organs. More...

Among the five million people living with lupus globally, nearly half develop lupus nephritis, a severe kidney inflammation that is a leading cause of death. Between 5% and 25% of patients with lupus nephritis die from kidney-related complications within five years of onset. Currently, monitoring kidney health relies on renal biopsies—painful, invasive procedures with risks of bleeding and infection, as well as subjectivity in interpretation. Now, monitoring kidney damage in lupus patients may soon become far less invasive.

A new study from the University of Houston (Houston, TX, USA) has found that urine samples can reveal the severity and progression of lupus nephritis—a major complication of systemic lupus erythematosus (SLE)—without requiring repeat renal biopsies. The discovery could transform disease management for millions worldwide. The new study aimed to identify noninvasive biomarkers capable of predicting kidney inflammation and scarring by analyzing urinary proteins through a large-scale proteomics approach.

Using 1,317 urine samples collected at the time of biopsy from patients with lupus nephritis, the researchers identified 57 proteins that were significantly elevated in individuals whose kidney tissue showed active damage. These elevated proteins were linked to microscopic signs such as vascular swelling, tissue necrosis, and clusters of injured cells—hallmarks of ongoing inflammation.

Further analysis revealed that some urinary proteins were also associated with chronic scarring, suggesting they could help clinicians distinguish between active disease and long-term damage. These findings, published in The Journal of Clinical Investigation, demonstrate that urine-based biomarkers could provide a reliable, repeatable, and noninvasive way to assess kidney disease activity and progression in lupus patients.

“Overall, the results indicate that by measuring certain proteins in urine, doctors might be able to tell how active or long-lasting someone’s lupus-related kidney disease is, and they could check kidney health without having to do another biopsy,” said Dr. Chandra Mohan, an international expert and pioneer in lupus research at the University of Houston.

Related Links:
University of Houston


Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
Steam Sterilizer
Hi Vac II Line
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.